Papulopustular Rosacea When Systemic Antibiotic Therapy Has Not Controlled Inflammatory Lesions

This protocol applies to papulopustular rosacea (subtype II) presenting with inflammatory papules and pustules in the central region of the face, accompanied by facial erythema — in patients for whom a prior course of systemic antibiotic therapy did not achieve adequate reduction of erythema and inflammatory lesions.

Clinical Presentation

Inflammatory papules and pustules localised to the central facial region, alongside facial erythema, are the defining features of subtype II rosacea. The primary treatment objective is improvement and remission of these papulopustular lesions.

Prior Treatment — Escalation Trigger

Systemic antibiotic therapy (oral doxycycline, tetracycline, or related agents) was used as the preceding line of management. When that approach fails to achieve sufficient reduction of erythema and inflammatory lesions, escalation to this next-step protocol is indicated.

Next-Step Approach

For patients whose papulopustular rosacea has not responded adequately to systemic antibiotics, the evidence supports a low-dose oral retinoid-class therapy as the next intervention. The complete regimen, including dosing, duration, and monitoring, is available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/jdv.14349

In subtype II, inflammatory papules and pustules are seen in the central region of the face.

Inflammatory lesions such as papules and pustules as well as erythema occur in subtype II.

Conclusion: Low-dose isotretinoin treatment (0.3 mg/kg) can be recommended (A) for subtype II rosacea patients.

From personal experience, we find that also a dose of 0.15 mg/kg can be effective.

A placebo-controlled, randomized clinical study with 573 patients of subtype II and III showed complete remissions in 24% and an improvement in 57% of patients treated with isotretinoin, using 0.3 mg/kg.

View source ↗